HCG on TRT: Preserving Fertility & Testicular Function

Last Updated: OCTOBER 2023

Men with total testosterone below 300 ng/dL exhibit significantly increased risks, including a 2.4x higher cardiovascular mortality rate (Journal of Clinical Endocrinology & Metabolism, 2018). While testosterone replacement therapy (TRT) effectively addresses symptoms of hypogonadism and improves quality of life, exogenous testosterone shuts down the body’s natural production of testosterone and, crucially, sperm. This suppression, mediated through the hypothalamic-pituitary-gonadal (HPG) axis, leads to testicular atrophy and impaired fertility. Human Chorionic Gonadotropin (HCG) stands as a critical adjunct to TRT, allowing men to maintain testicular function and preserve fertility.

Understanding HCG’s Role on TRT

When a man administers exogenous testosterone, such as 100–200mg testosterone cypionate or enanthate per week, the brain detects sufficient testosterone levels. In response, the hypothalamus reduces its production of Gonadotropin-Releasing Hormone (GnRH), which in turn signals the pituitary gland to cease secreting Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). LH is essential for stimulating the Leydig cells in the testes to produce testosterone, while FSH is crucial for spermatogenesis (sperm production) in the Sertoli cells. Without these signals, the testes shrink (atrophy) and sperm production diminishes, often leading to temporary or even permanent infertility.

HCG mimics the action of LH. By introducing HCG, we provide an artificial signal to the Leydig cells, prompting them to continue producing endogenous testosterone and maintaining testicular size. This direct stimulation helps circumvent the HPG axis shutdown caused by exogenous testosterone. The primary benefits of incorporating HCG into a TRT protocol are:

• Preservation of Testicular Size: Preventing the noticeable shrinkage that often occurs with TRT monotherapy.
• Maintenance of Endogenous Testosterone Production: While exogenous testosterone replaces the primary supply, HCG ensures the Leydig cells remain active, contributing to overall testicular health.
• Fertility Preservation: By sustaining Leydig cell function, HCG indirectly supports spermatogenesis, which is crucial for men who may desire children in the future.

The Gatekeeping of Fertility on TRT

Historically, fertility concerns were often used to gatekeep TRT from younger men or those who hadn’t completed their families. The arbitrary 264 ng/dL lower bound for total testosterone, established from a 1970s population that included sick and elderly individuals, frequently delayed treatment for men suffering from symptoms. With the understanding that TRT can impact fertility, HCG offers a science-backed solution, empowering men to address hypogonadism symptoms while preserving reproductive options. No man should be forced to choose between optimal health and the potential to father children.

HCG Dosing Protocols for Testicular Function and Fertility

Effective HCG dosing depends on the individual’s goals and response. Protocols are typically tailored to either prevent atrophy and maintain some endogenous function, or to actively restore/maximize fertility.

Maintaining Testicular Size and Function

For men on TRT primarily concerned with preventing testicular atrophy and maintaining a baseline level of endogenous testosterone production, lower, consistent HCG doses are generally effective.

• Standard Protocol: 500 IU (International Units) administered subcutaneously 2–3 times per week. This can be taken concurrently with testosterone injections (e.g., mixing HCG with bacterostatic water in a 5000 IU vial to get 500 IU/mL, then injecting 1mL 2x/week).
• Frequency: Splitting the dose helps maintain stable HCG levels, mirroring the pulsatile release of LH.
• Monitoring: Regular monitoring of testicular volume, subjective well-being, and potentially E2 levels is important.

Restoring or Maximizing Fertility

When fertility is the primary objective, higher doses of HCG, sometimes combined with other agents like FSH or enclomiphene, may be necessary. This often requires a more aggressive and closely monitored approach.

• Initial HCG-Only Fertility Protocol (for men on TRT): 1,000–2,000 IU of HCG administered subcutaneously 2–3 times per week. This aims to maximize Leydig cell stimulation. It’s crucial to perform a semen analysis after 3–6 months to assess sperm count and motility.
• Combination Therapy with FSH: If HCG monotherapy does not restore adequate sperm counts, recombinant Follicle-Stimulating Hormone (FSH) can be added. A protocol like the “Baylor 2025 protocol” involves HCG (e.g., 3,000 IU) combined with FSH (e.g., 75 IU) administered subcutaneously three times per week. This combination directly stimulates both Leydig cells (via HCG) and Sertoli cells (via FSH), enhancing spermatogenesis. Patel et al. (2019) in Fertility and Sterility noted that such combined therapies demonstrate significant potential for fertility restoration in men with hypogonadism.
• Enclomiphene as an Alternative/Adjunct: Enclomiphene, a selective estrogen receptor modulator (SERM), stimulates the pituitary to release LH and FSH. While often used as a standalone treatment for secondary hypogonadism, it can also be considered in conjunction with TRT or as a temporary bridge to restore fertility by enhancing endogenous gonadotropin production. It avoids direct testicular stimulation, instead working upstream.

“The goal of fertility preservation in men receiving testosterone replacement therapy is to maintain or restore spermatogenesis. HCG, by mimicking LH, is the cornerstone of this strategy, often augmented with FSH when necessary.” (Isidori et al., 2006, Journal of Andrology)

The timeline for fertility recovery varies significantly based on individual factors, including the duration of TRT, age, and baseline fertility. Recovery can take anywhere from 3 months to over a year. A semen analysis is the objective measure of success.

Comparing HCG Protocols

Monitoring and Side Effects

While HCG is generally well-tolerated, monitoring is crucial.

• Estradiol (E2) Management: HCG stimulates Leydig cells to produce testosterone, and some of this testosterone will aromatize into estradiol. Higher HCG doses can lead to elevated E2 levels, potentially causing side effects like gynecomastia, water retention, and mood swings. Regular E2 testing (e.g., sensitive E2 20–40 pg/mL on TRT) is essential. If E2 becomes elevated, a low dose of an aromatase inhibitor (AI) like anastrozole (e.g., 0.125–0.25mg once or twice per week) may be considered, but caution is advised to avoid crashing E2, which can also lead to adverse effects.
• Testicular Pain or Tenderness: Some men may experience mild testicular discomfort, especially with higher doses.
• Mood Changes: As with any hormone adjustment, mood fluctuations are possible.

For men on TRT, the decision to incorporate HCG is a proactive step toward comprehensive health management. It underscores a personalized approach to hormone therapy that respects individual goals, particularly regarding reproductive health.

Sources

1. Journal of Clinical Endocrinology & Metabolism. (2018). Association of Low Total Testosterone With Cardiovascular Mortality.
2. Patel, A. S., et al. (2019). The Impact of Exogenous Testosterone on Male Fertility: A Comprehensive Review. Fertility and Sterility, 112(1), 10–20.
3. Isidori, A. M., et al. (2006). Long-term effect of human chorionic gonadotropin on Leydig cell function in adult hypogonadal men. Journal of Andrology, 27(4), 540-547.